Davunetide (NAP): The Tau-Targeting Microtubule Peptide Getting a Second Act in 2026 (June 22, 2026)
Table of Contents
A peptide that works on the cell's scaffolding, not its chemistry
Most neuro-peptides researchers talk about act on signaling — they nudge a receptor, raise a growth factor, or tweak a neurotransmitter. Davunetide is different. It is an eight-amino-acid peptide, sequence NAPVSIPQ (hence its common name, NAP), and it works on the neuron's internal scaffolding: the microtubules. Microtubules are the rail system that holds a neuron's shape and ships cargo down its long axon. When they destabilize, the tau protein that normally binds them detaches, becomes hyperphosphorylated, and clumps into the tangles seen in Alzheimer's disease and other 'tauopathies.' Davunetide is a fragment of a larger human protein called activity-dependent neuroprotective protein (ADNP), which glial cells release in response to vasoactive intestinal peptide (VIP). In preclinical work it stabilizes microtubules — partly by interacting with the end-binding proteins EB1 and EB3 — and lowers tau hyperphosphorylation. That makes it one of the few clinically tested peptides aimed squarely at the cytoskeleton rather than at chemical signaling.
Where it came from
ADNP and NAP were discovered in the laboratory of Illana Gozes at Tel Aviv University. The peptide was picked up by Allon Therapeutics and developed as an intranasal spray under the code AL-108 (and AL-208 for an intravenous form). Intranasal delivery matters here: peptides are notoriously hard to get into the brain, and a nasal spray offered a non-invasive route to the central nervous system. Early-phase studies tested it in amnestic mild cognitive impairment — a precursor stage to Alzheimer's — and in schizophrenia, where cognition is often impaired. Those studies reported some short-term memory and functional signals and showed the spray was well tolerated, which set the stage for a much larger test in a 'pure' tauopathy.
The trial that didn't work
The pivotal test came in progressive supranuclear palsy (PSP), a relentless neurodegenerative disease driven almost entirely by tau. Because PSP is a clean tauopathy, it was an ideal place to ask whether a tau-protective peptide could change the course of disease. The phase 2/3 trial, published in Lancet Neurology in 2014, randomized 313 patients to intranasal davunetide (30 mg twice daily) or placebo for 52 weeks across dozens of centers on three continents. The result was unambiguous and disappointing: davunetide did not slow progression on either primary endpoint — the PSP Rating Scale or a scale of daily-living function. It was a well-run, adequately powered study, and it returned a clear negative. That is an important fact to keep front and center for any compound now sold to consumers under the davunetide name.
Why some researchers still find it interesting
A failed clinical trial does not erase a mechanism. The PSP result told us that this dose, on this schedule, did not help these patients — not that microtubule stabilization is a dead end. Lab work since then has deepened the mechanistic story: a 2023 study reported that davunetide actually penetrates the cell nucleus, which helps explain why such a small peptide has wide-ranging effects on gene expression and cytoskeletal repair, and other work describes a preferential interaction with the dynamic '3-repeat' form of tau, which may explain why it protects in some tauopathy models but not others. A 2025 review revisited intranasal NAP for neuroprotection and even its links to circadian biology. None of this is proof of human benefit — but it is why the molecule keeps drawing attention as a research tool for cytoskeletal neuroprotection.
The 2026 second act: a rare-disease pivot
The most concrete davunetide news in 2026 is not about Alzheimer's or general cognition — it is a narrowly focused rare-disease program. The peptide was relicensed from Tel Aviv University and is being developed as CP201, an intranasal formulation, for ADNP syndrome (also called Helsmoortel-Van der Aa syndrome). ADNP syndrome is a genetic neurodevelopmental disorder caused by mutations in the very gene davunetide is derived from, which makes it a rational — almost on-the-nose — target: a fragment of ADNP being tested in a disease of ADNP deficiency. CP201 carries U.S. FDA orphan-drug and rare-pediatric-disease designations and EMA orphan status, and a pediatric phase 3 program began in late 2024. This is a much more defined bet than 'improve memory in aging,' and it is the reason davunetide is back in the conversation.
What the evidence does and does not show
Here is the honest summary. Davunetide has a coherent, well-studied mechanism — microtubule stabilization and reduced tau phosphorylation — and a genuinely interesting biology, including nuclear penetration and tau-isoform selectivity. It also has a clear negative result in its one large, rigorous efficacy trial (PSP, 2014), and its earlier cognitive signals were exploratory and never confirmed. It is not approved for anything. Its only active clinical development is for a rare pediatric genetic disorder, where results are not yet in. For anyone tracking the peptide field, davunetide is valuable precisely as a worked example: a compound with strong preclinical neuroprotection that did not translate in a common tauopathy, now being re-aimed at the specific genetic disease its parent protein causes. Treat consumer 'research chemical' davunetide claims of cognitive enhancement with skepticism — the strongest human data point we have is a trial that did not work.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
- [1] Boxer AL et al. — Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014 Source
- [2] Davunetide — therapeutic profile and trial history. ALZFORUM Source
- [3] Gozes I. — The ADNP Syndrome and CP201 (NAP): Potential and Hope. PMC 2020 Source
- [4] Intranasal NAP (Davunetide): Neuroprotection and circadian rhythmicity. ScienceDirect 2025 Source
Related Articles
The FDA formally removes 12 peptides from Category 2 ahead of July PCAC hearings, LL-37 derivative research achieves improved stability and efficacy, dihexa produces measurable synaptogenesis in non-human primates, pentosan polysulfate shows 6-month disease modification in OA, and DSIP fusion peptides cross the blood-brain barrier.
Klotho: The 'Longevity Hormone' Being Tested to Slow Brain Aging — What the Science Actually Shows (June 16, 2026)
Klotho is a longevity hormone your body makes naturally. A single low-dose injection improved memory in aged monkeys, and a Phase 1 trial is now testing it in older adults. Here's what the evidence shows — and why klotho is a large protein, not a peptide you can buy.
Humanin: The Mitochondrial-Derived Peptide Behind the 2026 Longevity-Biomarker Buzz (June 21, 2026)
Humanin is an endogenous peptide encoded by your mitochondria that protects neurons, declines with age, and runs high in centenarians. Here is what the research actually shows in 2026 — and what it does not.